Back to INSMView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
3 competitors in Mycobacterium Infections, Nontuberculous
View Full LandscapeDrug Information
Target Indication
Mycobacterium Infections, Nontuberculous
Clinical Trial
NCT01315236Last updated: 12/4/2025
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.Phase 3
Pseudomonas Aeruginosa Infection
LAI 590 mgPhase 3
NTM Lung Infection Due to MAC
Liposomal amikacin for inhalationPhase 3
Cystic Fibrosis
Brensocatib 25 mgPhase 3
Non-Cystic Fibrosis Bronchiectasis
Treprostinil Palmitil Inhalation PowderPhase 3
Pulmonary Hypertension
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts